Preferences & Treatment Satisfaction Drivers in Rosacea Patients

LEO Pharma

Status: Completed

Conditions: Rosacea

Treatments: Drug: Brimonidine Tartrate Gel; Drug: Metronidazole cream; Drug: Metronidazole gel; Drug: Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251); Drug: Azelaic Acid Cream; Drug: Metronidazole Lotion; Drug: Metronidazole Emulsion

Study type: Observational

Funder types: Industry

Identifiers

NCT02602470

18575

Details and patient eligibility

About

To survey patients with rosacea about their rosacea treatment preferences as well as to assess potential drivers of rosacea treatment satisfaction.

Enrollment: 206 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female patients of at least 18 years of age at index date
• At least one prescription for a topical rosacea treatments: Azelaic Acid Gel, Azelaic Acid Cream, Metronidazole Gel, Metronidazole Cream, Metronidazole Emulsion, Metronidazole Lotion, Brimonidine Tartrate Gel
• At least one medical record with a diagnosis code for rosacea (ICD-9: 695.3)
• At least 6 months of data history prior to the index date
• Had at least one encounter at the Reliant Medical Group within 3 months prior to 01 January 2015

Exclusion criteria

• None

Trial design

206 participants in 1 patient group

Rosacea treated patients

Description:

Patients using topical rosacea treatment

Treatment:

Drug: Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)

Drug: Brimonidine Tartrate Gel

Drug: Metronidazole cream

Drug: Metronidazole Lotion

Drug: Metronidazole gel

Drug: Azelaic Acid Cream

Drug: Metronidazole Emulsion